France’s Servier gets FDA green light for oral drug to treat brain cancer
Servier Pharmaceuticals, the US arm of a French pharmaceutical company, got approval from the US drug regulator for a once-daily pill to treat.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Servier Pharmaceuticals, the US arm of a French pharmaceutical company, got approval from the US drug regulator for a once-daily pill to treat.
British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.
The national public health agency of the US has reported a fourth person who was infected in the country with the highly pathogenic.
The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary.
The US drug regulator has granted accelerated approval for a drug to treat chronic inflammatory liver disease to Genfit, headquartered in Nord, France,.
HQ Team May 13, 2024: Pfizer and AstraZeneca will invest about $1 billion separately in France to set up and expand facilities, Finance.
HQ Team January 8, 2024: About 17,000 people may have died in six countries after using antimalarial drug hydroxychloroquine during the first wave.
HQ Team December 6, 2023: France has upgraded its level of bird flu risk to ‘high’ from ‘moderate’ to ensure better protection and.
HQ Team December 4, 2023: The COP28 has unveiled a $1.7 billion funding plan to meet climate and diversity goals. The key objectives.
HQ Team November 29, 2023: The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global.